SCHEDULE: Canaan Funds Divest Entire Stake in Cidara Therapeutics
Beneficial Ownership Amendment
Canaan XII L.P. and Canaan Partners XII LLC have fully divested their beneficial ownership in Cidara Therapeutics, Inc., holding 0% of common stock as of June 30, 2025.
Summary
- Canaan XII L.P., a Cayman Islands limited partnership, and Canaan Partners XII LLC, a Delaware limited liability company, are the reporting persons.
- As of June 30, 2025, the reporting persons beneficially own 0.0% of the common stock of Cidara Therapeutics, Inc.
- This filing is an Amendment No. 1 to a previous Schedule 13G, indicating a change from a prior beneficial ownership position.
- The reporting persons hold no sole or shared voting power and no sole or shared dispositive power over Cidara Therapeutics shares.
- The securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 4
Explanation: The complete divestment by a venture capital firm, Canaan Partners, from Cidara Therapeutics is generally perceived as a negative signal, as it indicates a lack of continued confidence or a strategic exit from the investment.
Negatives
- Canaan XII L.P. and Canaan Partners XII LLC have completely divested their beneficial ownership in Cidara Therapeutics, Inc., holding 0% of the common stock.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding Cidara Therapeutics, Inc.'s future operations or financial performance.
Industry Context
This filing reflects a specific investment firm's decision to exit its position in a biotechnology company. While not indicative of broader industry trends, it represents a change in institutional investor sentiment or portfolio strategy concerning Cidara Therapeutics, Inc.
Stakeholder Impact
- Shareholders: The complete divestment by a significant institutional investor may be interpreted negatively by existing and potential shareholders, potentially influencing stock price and investor confidence.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which required the filing of this statement, indicating the effective date of 0% beneficial ownership. |
| 08/14/2025 | Signature date of the Schedule 13G Amendment No. 1 filing by Nancy Levenson, Attorney-in-Fact for both reporting persons. |
Keywords
Cidara Therapeutics, Canaan XII L.P., Canaan Partners XII LLC, Schedule 13G, Beneficial Ownership, Divestment, Common Stock, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.